Literature DB >> 16395294

Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine.

Jesse R Schank1, Rossella Ventura, Stefano Puglisi-Allegra, Antonio Alcaro, Charlene D Cole, L Cameron Liles, Philip Seeman, David Weinshenker.   

Abstract

Multiple lines of evidence demonstrate that the noradrenergic system provides both direct and indirect excitatory drive onto midbrain dopamine (DA) neurons. We used DA beta-hydroxylase (DBH) knockout (Dbh-/-) mice that lack norepinephrine (NE) to determine the consequences of chronic NE deficiency on midbrain DA neuron function in vivo. Basal extracellular DA levels were significantly attenuated in the nucleus accumbens (NAc) and caudate putamen (CP), but not prefrontal cortex (PFC), of Dbh-/- mice, while amphetamine-induced DA release was absent in the NAc and attenuated in the CP and PFC. The decrease in dopaminergic tone was associated with a profound increase in the density of high-affinity state D1 and D2 DA receptors in the NAc and CP, while DA receptors in the PFC were relatively unaffected. As a behavioral consequence of these neurochemical changes, Dbh-/- mice were hypersensitive to the psychomotor, rewarding, and aversive effects of cocaine, as measured by locomotor activity and conditioned place preference. Antagonists of DA, but not 5-HT, receptors attenuated the locomotor hypersensitivity to cocaine in Dbh-/- mice. As DBH activity in humans is genetically controlled and the DBH inhibitor disulfiram has shown promise as a pharmacotherapy for cocaine dependence, these results have implications for the influence of genetic and pharmacological DBH inhibition on DA system function and drug addiction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16395294     DOI: 10.1038/sj.npp.1301000

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  60 in total

Review 1.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

2.  Differential effects of acute and chronic treatment with the α2-adrenergic agonist, lofexidine, on cocaine self-administration in rhesus monkeys.

Authors:  Stephen J Kohut; Peter A Fivel; Nancy K Mello
Journal:  Drug Alcohol Depend       Date:  2013-08-11       Impact factor: 4.492

3.  Dissociation of β1- and β2-adrenergic receptor subtypes in the retrieval of cocaine-associated memory.

Authors:  Michael K Fitzgerald; James M Otis; Devin Mueller
Journal:  Behav Brain Res       Date:  2015-08-28       Impact factor: 3.332

4.  Dopamine beta-hydroxylase-deficient mice have normal densities of D(2) dopamine receptors in the high-affinity state based on in vivo PET imaging and in vitro radioligand binding.

Authors:  Mette Skinbjerg; Nicholas Seneca; Jeih-San Liow; Jinsoo Hong; David Weinshenker; Victor W Pike; Christer Halldin; David R Sibley; Robert B Innis
Journal:  Synapse       Date:  2010-09       Impact factor: 2.562

5.  Effects of pharmacologic dopamine β-hydroxylase inhibition on cocaine-induced reinstatement and dopamine neurochemistry in squirrel monkeys.

Authors:  Debra A Cooper; Heather L Kimmel; Daniel F Manvich; Karl T Schmidt; David Weinshenker; Leonard L Howell
Journal:  J Pharmacol Exp Ther       Date:  2014-05-09       Impact factor: 4.030

Review 6.  Targeting the noradrenergic system for gender-sensitive medication development for tobacco dependence.

Authors:  Terril L Verplaetse; Andrea H Weinberger; Philip H Smith; Kelly P Cosgrove; Yann S Mineur; Marina R Picciotto; Carolyn M Mazure; Sherry A McKee
Journal:  Nicotine Tob Res       Date:  2015-03-11       Impact factor: 4.244

7.  DBH gene as predictor of response in a cocaine vaccine clinical trial.

Authors:  Thomas R Kosten; Coreen B Domingo; Sara C Hamon; David A Nielsen
Journal:  Neurosci Lett       Date:  2013-02-28       Impact factor: 3.046

8.  Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.

Authors:  Laura M Butkovich; Madelyn C Houser; Termpanit Chalermpalanupap; Kirsten A Porter-Stransky; Alexa F Iannitelli; Jake S Boles; Grace M Lloyd; Alexandra S Coomes; Lori N Eidson; Maria Elizabeth De Sousa Rodrigues; Danielle L Oliver; Sean D Kelly; Jianjun Chang; Nora Bengoa-Vergniory; Richard Wade-Martins; Benoit I Giasson; Valerie Joers; David Weinshenker; Malú Gámez Tansey
Journal:  J Neurosci       Date:  2020-08-31       Impact factor: 6.167

9.  Alpha2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment.

Authors:  Sudhirkumar U Yanpallewar; Kimberly Fernandes; Swananda V Marathe; Krishna C Vadodaria; Dhanisha Jhaveri; Karen Rommelfanger; Uma Ladiwala; Shanker Jha; Verena Muthig; Lutz Hein; Perry Bartlett; David Weinshenker; Vidita A Vaidya
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

10.  Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.

Authors:  Thomas R Kosten; Guiying Wu; Wen Huang; Mark J Harding; Sara C Hamon; Jaakko Lappalainen; David A Nielsen
Journal:  Biol Psychiatry       Date:  2012-08-18       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.